Literature DB >> 6092569

Preparation of four fluorine- 18-labeled estrogens and their selective uptakes in target tissues of immature rats.

D O Kiesewetter, M R Kilbourn, S W Landvatter, D F Heiman, J A Katzenellenbogen, M J Welch.   

Abstract

Four fluorine- 18-labeled estrogens--16 alpha-[18F]fluoro-estradiol-17 beta (1), 16 beta-[18F]fluoro-estradiol-17 beta (2), (2R, 3S)-1-[18F]fluoro-2,3-bis(4-hydroxyphenyl)-pentane (1-[18F]fluoropentestrol) (3), and (3R, 4S)-1-[18F]fluoro-3,4-bis(4-hydroxyphenyl)hexane (1-[18F]fluorohexestrol) (4)--have been prepared by simple displacement reactions utilizing reactive trifluoromethane sulfonate (triflate) precursors and F-18 fluoride ion. All four fluoroestrogens have high affinity for the estrogen receptor. In immature female rats, they are taken up by target tissues, such as the uterus, with very high selectivity: uterus-to-blood ratios at 1 hr are: Compound 1, 39; Compound 2, 12; Compound 3, 13; and Compound 4, 19. Average uterus-to-blood ratios exceed 80 for Compound 1 at 2 hr. That the uptake process involves an estrogen-specific binder of limited capacity is demonstrated by the suppressive effect of coadministered unlabeled estradiol on target tissue uptake.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6092569

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  43 in total

1.  Small-animal PET of steroid hormone receptors predicts tumor response to endocrine therapy using a preclinical model of breast cancer.

Authors:  Amy M Fowler; Szeman Ruby Chan; Terry L Sharp; Nicole M Fettig; Dong Zhou; Carmen S Dence; Kathryn E Carlson; M Jeyakumar; John A Katzenellenbogen; Robert D Schreiber; Michael J Welch
Journal:  J Nucl Med       Date:  2012-06-05       Impact factor: 10.057

Review 2.  Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors.

Authors:  D A Mankoff; F Dehdashti; A F Shields
Journal:  Neoplasia       Date:  2000 Jan-Apr       Impact factor: 5.715

Review 3.  Targeted functional imaging in breast cancer.

Authors:  Rakesh Kumar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-03       Impact factor: 9.236

4.  Imaging readouts as biomarkers or surrogate parameters for the assessment of therapeutic interventions.

Authors:  Markus Rudin
Journal:  Eur Radiol       Date:  2007-03-06       Impact factor: 5.315

5.  Basic evaluation of FES-hERL PET tracer-reporter gene system for in vivo monitoring of adenoviral-mediated gene therapy.

Authors:  Talakad Goolaiah Lohith; Takako Furukawa; Tetsuya Mori; Masato Kobayashi; Yasuhisa Fujibayashi
Journal:  Mol Imaging Biol       Date:  2008-06-12       Impact factor: 3.488

6.  Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer.

Authors:  Lanell M Peterson; Brenda F Kurland; Jeanne M Link; Erin K Schubert; Svetlana Stekhova; Hannah M Linden; David A Mankoff
Journal:  Nucl Med Biol       Date:  2011-05-05       Impact factor: 2.408

7.  Synthesis and biological evaluation of two agents for imaging estrogen receptor β by positron emission tomography: challenges in PET imaging of a low abundance target.

Authors:  Jae Hak Lee; Olaf Peters; Lutz Lehmann; Carmen S Dence; Terry L Sharp; Kathryn E Carlson; Dong Zhou; M Jeyakumar; Michael J Welch; John A Katzenellenbogen
Journal:  Nucl Med Biol       Date:  2012-06-30       Impact factor: 2.408

8.  Determination of binding affinity of molecular imaging agents for steroid hormone receptors in breast cancer.

Authors:  Kelley Salem; Manoj Kumar; Kyle C Kloepping; Ciara J Michel; Yongjun Yan; Amy M Fowler
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-04-25

Review 9.  Fluorinated tracers for imaging cancer with positron emission tomography.

Authors:  Olivier Couturier; André Luxen; Jean-François Chatal; Jean-Philippe Vuillez; Pierre Rigo; Roland Hustinx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-06       Impact factor: 9.236

Review 10.  Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET.

Authors:  Mark P S Dunphy; Jason S Lewis
Journal:  J Nucl Med       Date:  2009-04-20       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.